Literature DB >> 29920250

FcγRI (CD64) contributes to the severity of immune inflammation through regulating NF-κB/NLRP3 inflammasome pathway.

Hongfeng Zhang1, Ling Li2, Lei Liu2.   

Abstract

AIMS: Fcγ receptor I (FcγRI/CD64) that is restrictedly expressed on monocytes and macrophages, acts as the single high-affinity receptor of immunoglobulin G (IgG) in human. The expression of FcγRI is positively correlated with immune inflammation. The primary aim of this study was to explore the effects of FcγRI expression on immune-related inflammatory response and investigate the potential mechanisms. MAIN
METHODS: FcγRI-expressing Ba/F3 cells are the ideal models for evaluating the functions of FcγRI. Nuclear factor kappa B (NF-κB) and NOD-like receptor protein 3 (NLRP3) inflammasome-associated protein expressions and inflammatory cytokine (IL-1β and IL-18) release were detected in the presence or absence of NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC). Besides, the effects of FcγRI on the activation of the NLRP3 inflammasomes were also investigated in THP-1 macrophages deficient for FcγRI. KEY
FINDINGS: FcγRI-expressing Ba/F3 cells appeared increased NLRP3 inflammasome formation and IL-1β and IL-18 release via activating NF-κB signaling. Interestingly, this alteration could be reversed in THP-1 macrophages after FcγRI was silenced. SIGNIFICANCE: These results indicated that FcγRI functioned as a regulator for immune inflammation via acceleration of NF-κB regulating NLRP3 inflammasome signaling.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FcγRI; Immune inflammation; NF-κB; NLRP3 inflammasomes

Mesh:

Substances:

Year:  2018        PMID: 29920250     DOI: 10.1016/j.lfs.2018.06.015

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  The Role of Antibodies Against the Crude Capsular Extract in the Immune Response of Porcine Alveolar Macrophages to In Vitro Infection of Various Serovars of Glaesserella (Haemophilus) parasuis.

Authors:  Katarína Matiašková; Lenka Kavanová; Pavel Kulich; Jan Gebauer; Kateřina Nedbalcová; Hana Kudláčková; Radek Tesařík; Martin Faldyna
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

2.  A Prognostic Pyroptosis-Related lncRNAs Risk Model Correlates With the Immune Microenvironment in Colon Adenocarcinoma.

Authors:  Fada Xia; Yuanliang Yan; Cong Shen
Journal:  Front Cell Dev Biol       Date:  2021-12-13

3.  Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells.

Authors:  Simon Hultmark; Aurélie Baudet; Ludwig Schmiderer; Pavan Prabhala; Sara Palma-Tortosa; Carl Sandén; Thoas Fioretos; Rajkumar Sasidharan; Christer Larsson; Sören Lehmann; Gunnar Juliusson; Fredrik Ek; Mattias Magnusson
Journal:  Haematologica       Date:  2021-10-01       Impact factor: 9.941

4.  System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.

Authors:  Cheng Yan; Yandie Niu; Feng Li; Wei Zhao; Liukai Ma
Journal:  J Transl Med       Date:  2022-10-05       Impact factor: 8.440

5.  Identification of Key Gene Targets for Periodontitis Treatment by Bioinformatics Analysis.

Authors:  Ying Jin; Ye Wang; Xiaoping Lin
Journal:  Biomed Res Int       Date:  2022-09-29       Impact factor: 3.246

6.  A role for the immune system in advanced laryngeal cancer.

Authors:  Marta Tagliabue; Fausto Maffini; Caterina Fumagalli; Sara Gandini; Daniela Lepanto; Federica Corso; Salvatore Cacciola; Alberto Ranghiero; Alessandra Rappa; Davide Vacirca; Maria Cossu Rocca; Daniela Alterio; Elena Guerini Rocco; Augusto Cattaneo; Francesco Chu; Stefano Zorzi; Giuseppe Curigliano; Susanna Chiocca; Massimo Barberis; Giuseppe Viale; Mohssen Ansarin
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.